The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Multi-institutional review of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle-invasive bladder cancer.
Andrew J. Lightfoot
No relevant relationships to disclose
Benjamin N. Breyer
No relevant relationships to disclose
Henry M. Rosevear
No relevant relationships to disclose
Badrinath Konety
No relevant relationships to disclose
Michael A. O'Donnell
No relevant relationships to disclose